



(12) Translation of
European patent specification

(11) NO/EP 3433256 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/4738 (2006.01)
A61K 31/497 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2020.01.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.08.07
(86)	European Application Nr.	17783857.0
(86)	European Filing Date	2017.10.13
(87)	The European Application's Publication Date	2019.01.30
(30)	Priority	2016.10.24, US, 201662411799 P 2016.12.16, US, 201662435159 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Astrazeneca AB, 151 85 Södertälje, Sverige
(72)	Inventor	SCOTT, James, Stewart, AstraZeneca Darwin BuildingCambridge Science ParkMilton Road, CambridgeCambridgeshire CB4 0WG, Storbritannia BARLAAM, Bernard, Christophe, AstraZenecaDarwin Building Cambridge Science ParkMilton Road, CambridgeCambridgeshire CB4 0WG, Storbritannia YANG, Bin, AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451, USA MOSS, Thomas, Andrew, AstraZenecaDarwin Building Darwin BuildingCambridge Science ParkMilton Road, CambridgeCambridgeshire CB4 0WG, Storbritannia HUGHES, Samantha, Jayne, AstraZeneca Darwin BuildingCambridge Science ParkMilton Road, CambridgeCambridgeshire CB4 0WG, Storbritannia NISSINK, Johannes, Wilhelmus, Maria, AstraZenecaDarwin Building Cambridge Science ParkMilton Road, CambridgeCanbridgeshire CB4 0WG, Storbritannia O'DONOVAN, Daniel, Hillebrand, AstraZeneca Darwin BuildingCambridge Science ParkMilton Road, CambridgeCambridgeshire CB4 0WG, Storbritannia
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER
------	-------	---

(56) References


Cited: WO-A1-2017/174757
WO-A1-2016/202161
WO-A1-2016/097072

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. N-(1-(3-fluorpropyl)azetidin-3-yl)-6-((6S,8R)-8-metyl-7-(2,2,2-trifluoretyl)-6,7,8,9-


5 tetrahydro-3H-pyrazolo[4,3-f]isokinolin-6-yl)pyridin-3-amin,



eller et farmasøytisk akseptabelt salt derav.

2. Forbindelsen ifølge krav 1 som er N-(1-(3-fluorpropyl)azetidin-3-yl)-6-((6S,8R)-8-

10 metyl-7-(2,2,2-trifluoretyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isokinolin-6-yl)pyridin-3-amin



3. Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel eksipiens.

15

4. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt derav, for anvendelse som et medikament.

5. Forbindelse for anvendelse ifølge krav 4, for anvendelse i forebygging eller behandling

20

6. Forbindelse for anvendelse ifølge krav 5, hvori kreften er bryst- eller gynekologisk kreft.